MIV tests SagaX' embolic protection technology
This article was originally published in Clinica
Executive Summary
MIV Therapeutics is beginning animal trials of an embolic protection device for catching blood clots that become dislodged during cardiac procedures and can travel to the brain and cause a stroke. The aortic embolic protection device (AEPD) was developed by SagaX Medical Technologies, a company recently acquired by MIV (see Clinica No 1150, p 14). The AEPD, which is placed in a main artery, is designed for use during invasive heart procedures such as electrophysiology, valve dilatations and valve repair through angioplasty. The technology may also find broad preventative application during minimally invasive alternatives to open surgery, said Vancouver, British Columbia-based MIV, which estimates the product's market to exceed $1.5-1.8bn by 2009.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.